Artificial intelligence (AI) is expected to cause significant medical quality enhancements and cost-saving improvements in ophthalmology. Although there has been a rapid growth of studies on AI in the recent years, real-world adoption of AI is still rare. One reason may be because the data derived from economic evaluations of AI in health care, which policy makers used for adopting new technology, have been fragmented and scarce. Most data on economics of AI in ophthalmology are from diabetic retinopathy (DR) screening. Few studies classified costs of AI software, which has been considered as a medical device, into direct medical costs. These costs of AI are composed of initial and maintenance costs. The initial costs may include investment in research and development, and costs for validation of different datasets. Meanwhile, the maintenance costs include costs for algorithms upgrade and hardware maintenance in the long run. The cost of AI should be balanced between manufacturing price and reimbursements since it may pose significant challenges and barriers to providers. Evidence from cost-effectiveness analyses showed that AI, either standalone or used with humans, was more cost-effective than manual DR screening. Notably, economic evaluation of AI for DR screening can be used as a model for AI to other ophthalmic diseases.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/APO.0000000000000403 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Screening Tomosynthesis Trial with Advanced Reader Methods (STREAM): design and rationale of a population-based breast cancer screening trial.
Eur Radiol
January 2025
Radboud University Medical Center, IQ Health science department, Nijmegen, The Netherlands.
Objectives: It is uncertain what the effects of introducing digital breast tomosynthesis (DBT) in the Dutch breast cancer screening programme would be on detection, recall, and interval cancers (ICs), while reading times are expected to increase. Therefore, an investigation into the efficiency and cost-effectiveness of DBT screening while optimising reading is required.
Materials And Methods: The Screening Tomosynthesis trial with advanced REAding Methods (STREAM) aims to include 17,275 women (age 50-72 years) eligible for breast cancer screening in the Netherlands for two biennial DBT screening rounds to determine the short-, medium-, and long-term effects and acceptability of DBT screening and identify an optimised strategy for reading DBT.
Public Health.
Alzheimers Dement
December 2024
University of Southern California, Los Angeles, CA, USA.
Background: The value payers and policymakers traditionally place on novel treatments for Alzheimer's and other neurological diseases that cause cognitive impairment (CI) and dementia often ignores disease baseline severity. More patient-centered economic evaluations-such as those estimating "insurance value"-incorporate the fact that individuals are typically risk-averse and place high value on generous coverage of treatments in the event that they develop CI, such as severe dementia, later in life. This study aims to estimate this insurance value, accounting for risk aversion, relative to the value of the same treatment based on traditional payer cost effectiveness approaches.
View Article and Find Full Text PDFPodiatric Clinical Triage in a Foot and Ankle Orthopaedic Clinic: A Randomised Trial.
J Eval Clin Pract
February 2025
Department of Orthopaedics and Trauma, Gold Coast Hospital and Health Service, Southport, Queensland, Australia.
Rationale: Hospitals are increasingly utilising allied-health professionals to provide clinical triage to patients. While these positions are routinely implemented, and several observational studies have reported positive outcomes, the effectiveness of this intervention has been rarely tested in a clinical trial.
Aims And Objectives: The objectives of this study were to (i) evaluate a podiatry-led orthopaedic triage service using patient-reported outcome measures (PROMs), and (ii) determine if it is cost-effective in terms of incremental cost/quality-adjusted life years (QALYs).
Background: Recent developments in blood biomarkers (BBM) have shown promising results in diagnosing amyloid pathology in Alzheimer's Disease (AD). However, information on how these BBMs can best be used in clinical settings to optimise clinical decision-making and long-term health outcomes for individuals with AD is still lacking. We aim to assess the potential clinical and economic value of BBM in AD diagnosis within the context of disease-modifying treatment (DMT).
View Article and Find Full Text PDFBackground: Some individual-level interventions for dementia risk factors could be cost saving. We aimed to estimate the cost effectiveness of population-level interventions for tackling dementia risk factors. We found such interventions for tobacco smoking, excess alcohol use, diet modification to decrease hypertension and obesity, air pollution, and head injury.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!